- Home
- RC vs SIGA Comparison
RC vs SIGA Comparison
Compare RC & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RC | SIGA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.8M | 471.2M |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | RC | SIGA |
|---|---|---|
| Price | $2.30 | $6.73 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.94 | N/A |
| AVG Volume (30 Days) | ★ 3.5M | 330.2K |
| Earning Date | 03-02-2026 | 03-10-2026 |
| Dividend Yield | 1.71% | ★ 9.01% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $172,249,641.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.33 | $132.36 |
| P/E Ratio | ★ N/A | $6.47 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.97 | $4.95 |
| 52 Week High | $7.12 | $9.62 |
Technical Indicators
Market Signals| Indicator | RC | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 50.86 | 58.07 |
| Support Level | $2.05 | $6.41 |
| Resistance Level | $2.46 | $6.77 |
| Average True Range (ATR) | 0.12 | 0.22 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 64.29 | 79.87 |
Price Performance
Historical ComparisonAbout RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.